Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s169154
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2018
Authors
Publisher
Informa UK Limited